400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
2018-12-21
FDA-2018-D-4455
指导原则
美国
现行有效
/
美国食品药品监督管理局(FDA)
GUIDANCE DOCUMENT
Not for implementation. Contains non-binding recommendations.
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled “Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data.” This draft guidance is being developed under the 21st Century Cures Act (Cures Act), which directs FDA to issue guidance on how a person seeking to develop and submit a proposed draft guidance relating to patient experience data for consideration by FDA may submit such proposed draft guidance to the Agency.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2018-D-4455.
摩熵医械2026-01-28
摩熵医械2026-01-13
摩熵医械2025-12-19
赛柏蓝2025-12-12
摩熵医械2025-11-28
摩熵医械2025-11-17
赛柏蓝2025-11-14
摩熵医械2025-11-12
赛柏蓝2025-11-12
CHC医疗传媒2025-10-30
2026-03-04
2026-03-02
2026-03-02
2026-02-28
2026-02-28
2026-02-24
2026-02-24
2026-02-12
2026-02-10
2026-02-06
2026-02-06
2026-02-06
2026-02-04
2026-02-04
2026-01-30
2024-11-15
2024-11-14
2024-11-01
2024-10-31
2024-10-30
2024-10-24
2024-10-22
2024-10-21
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-16
2024-10-15
2025-11-17
2025-09-17
2025-09-17
2025-09-17
2025-07-21
2025-02-05
2025-01-31
2025-01-31
2025-01-07
2025-01-07
2025-01-07
2025-01-07
2025-01-07
2025-01-07
2025-01-07